United Therapeutics Corp/ US91307C1027 /
| 2024-04-30 9:59:50 PM | Chg. -3.93 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 234.52USD | -1.65% | 43,171 Turnover: 10.16 mill. |
-Bid Size: - | -Ask Size: - | 11.03 bill.USD | - | 11.14 |
Assets
| 2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 465 | 478.4210 | 495.7740 | 489.3000 | 545.7000 | ||||||
| Intangible Assets | 14.1000 | - | - | - | - | ||||||
| Long-Term Investments | - | 122.7870 | 38.0020 | 2.3000 | 502.7000 | ||||||
| Fixed Assets | - | - | - | - | 1,431.5000 | ||||||
| Inventories | 47.8000 | 66.9270 | 81.3340 | 100 | 107.9000 | ||||||
| Accounts Receivable | 126.3000 | 162.2870 | 192.8270 | 214.5000 | 297.1000 | ||||||
| Cash and Cash Equivalents | 278.9000 | 397.6970 | 831.7980 | 1,023 | 705.1000 | ||||||
| Current Assets | 909 | 974.1970 | 1,275.3350 | 1,424.8000 | 1,447.9000 | ||||||
| Total Assets | 2,087.6000 | 1,884.4100 | 2,184.4450 | 2,325.6000 | 2,879.4000 | ||||||
Liabilities
| 2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 0.0000 | - | - | - | - | ||||||
| Long-term debt | 3.7000 | - | - | - | 250 | ||||||
| Liabilities to Banks | 3.7000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 783.3000 | 642.0540 | 595.8930 | 474.3000 | 777.6000 | ||||||
| Share Capital | .6300 | .6600 | .6900 | .7000 | .7000 | ||||||
| Total Equity | 1,304.3000 | 1,242.3560 | 1,588.5520 | 1,851.3000 | 2,101.8000 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 2,087.6000 | 1,884.4100 | 2,184.4450 | 2,325.6000 | 2,879.4000 | ||||||
Income Statement
| 2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 1,117 | 1,288.5190 | 1,465.7610 | 1,598.8000 | 1,725.3000 | ||||||
| Depreciation (total) | - | 32.2450 | 32.9210 | - | - | ||||||
| Operating Result | 292.5000 | 538.8000 | 699.0150 | 1,061.7000 | 814.9000 | ||||||
| Interest Income | -14.3000 | -17.5920 | -4.7350 | -3.9000 | -9 | ||||||
| Income Before Taxes | 278.9000 | 525.1800 | 1,044.4370 | 1,060.2000 | 769.5000 | ||||||
| Income Taxes | 104.3000 | -185.1060 | -392.7980 | -346.5000 | -351.6000 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | 174.6000 | 340.0740 | 651.6390 | 713.7000 | 417.9000 | ||||||
Per Share
Cash Flow
| 2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 425.3000 | 355.2590 | 382.7610 | 643.6000 | 474.2000 | ||||||
| Cash Flow from Investing Activities | -295 | 338.4650 | 503.5790 | 48.3000 | -835.6000 | ||||||
| Cash Flow from Financing | -5.1000 | -576.5350 | -446.9430 | -497.7000 | 43.3000 | ||||||
| Decrease / Increase in Cash | 124.9000 | 113.4390 | 434.1010 | 191.2000 | -317.9000 | ||||||
| Employees | 706 | 740 | 750 | 750 | 800 | ||||||
